

NHO GMP & ISO: 9001-2008 Certified Company

Corp. Off.: 502, Kanakia Atrium - 2, Next to Courtyard Marriott Hotel, Andheri Kurla Road, Andheri (East), Mumbai - 400 093 (India) Ph.: + 91 22 61933100 Fax: +91 22 61933114

14th November, 2016

**BSE Limited** 

Phiroze Jeejeebhoy Towers Dalal Street Mumbai-400001

Kind Attn: General Manager-DCS

Scrip Code: 533543

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai-400051

Kind Attn: Head-Listing

Symbol: BROOKS

Sub: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Dear Sirs,

This has in reference to the regulation mentioned above:

We hereby inform you that the Board of Directors at its meeting held today has, inter alia, approved the Unaudited Financial Results of the Company for the 2<sup>nd</sup> guarter ended 30<sup>th</sup> September, 2016. The Audit Committee reviewed the Unaudited Financial Results at its meeting held earlier today which have been subjected to a limited review by the Statutory Auditors. The Statement of Unaudited Financial Results, together with the Limited Review Report is attached.

This is for your information and record. Thanking You,

Yours faithfully

For BROOKS LABORATORIES LIMITED

(Jyoti Sancheti)

**Company Secretary cum Compliance Officer** 

Encl.: As Stated Above

## **BROOKS LABORATORIES LIMITED**

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

Tel No: +91 1795 654001/02/03, Fax No: +91 1795 236939, E-mail: investors@brookslabs.net, Website: www.brookslabs.net
Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2016

(Rs. In lacs)

Income from operations	0.09.2016	3,844.88 3,844.88 3,844.88 2,621.00 21.84 318.22 56.57 453.62	8,000.94 8,000.94 5,259.55 34.68 707.84 116.00
1   Income from operations (a) Net sales   1,609.68   1,599.18   2,047.17     Total income from operations (net)   1,609.68   1,599.18   2,047.17     2   Expenses (a) Cost of materials consumed (b) Changes in inventories of finished goods & work-in-progress (37.63)   63.60 (7.75) (c) Employee benefits expense (4) Depreciation and amortization expense (33.54 (30.34 28.53)	3,208.86 3,208.86 1,686.02 25.97 382.76 63.88 295.03 359.96	3,844.88 3,844.88 2,621.00 21.84 318.22 56.57	8,000.94 8,000.94 5,259.55 34.68 707.84
Income from operations (a) Net sales	3,208.86 3,208.86 1,686.02 25.97 382.76 63.88 295.03 359.96	3,844.88 3,844.88 2,621.00 21.84 318.22 56.57	8,000.94 8,000.94 5,259.55 34.68 707.84
(a) Net sales       1,609.68       1,599.18       2,047.17         Total income from operations (net)       1,609.68       1,599.18       2,047.17         2 Expenses       (a) Cost of materials consumed       862.08       823.94       1,361.99         (b) Changes in inventories of finished goods & work-in-progress       (37.63)       63.60       (7.75)         (c) Employee benefits expense       190.14       192.62       187.18         (d) Depreciation and amortization expense       33.54       30.34       28.53	1,686.02 25.97 382.76 63.88 295.03 359.96	3,844.88 2,621.00 21.84 318.22 56.57	5,259.55 34.68 707.84
Total income from operations (net)  2 Expenses (a) Cost of materials consumed (b) Changes in inventories of finished goods & work-in-progress (c) Employee benefits expense (d) Depreciation and amortization expense  1,609.68 1,599.18 2,047.17  862.08 823.94 1,361.99 (37.63) 63.60 (7.75) 190.14 192.62 187.18 30.34 28.53	1,686.02 25.97 382.76 63.88 295.03 359.96	3,844.88 2,621.00 21.84 318.22 56.57	5,259.55 34.68 707.84
2 Expenses       862.08       823.94       1,361.99         (b) Changes in inventories of finished goods & work-in-progress       (37.63)       63.60       (7.75)         (c) Employee benefits expense       190.14       192.62       187.18         (d) Depreciation and amortization expense       33.54       30.34       28.53	1,686.02 25.97 382.76 63.88 295.03 359.96	2,621.00 21.84 318.22 56.57	5,259.55 34.68 707.84
(a) Cost of materials consumed       862.08       823.94       1,361.99         (b) Changes in inventories of finished goods & work-in-progress       (37.63)       63.60       (7.75)         (c) Employee benefits expense       190.14       192.62       187.18         (d) Depreciation and amortization expense       33.54       30.34       28.53	25.97 382.76 63.88 295.03 359.96	21.84 318.22 56.57	34.68 707.84
(b) Changes in inventories of finished goods & work-in-progress       (37.63)       63.60       (7.75)         (c) Employee benefits expense       190.14       192.62       187.18         (d) Depreciation and amortization expense       33.54       30.34       28.53	25.97 382.76 63.88 295.03 359.96	21.84 318.22 56.57	34.68 707.84
(b) Changes in inventories of finished goods & work-in-progress       (37.63)       63.60       (7.75)         (c) Employee benefits expense       190.14       192.62       187.18         (d) Depreciation and amortization expense       33.54       30.34       28.53	25.97 382.76 63.88 295.03 359.96	21.84 318.22 56.57	34.68 707.84
(c) Employee benefits expense     190.14     192.62     187.18       (d) Depreciation and amortization expense     33.54     30.34     28.53	382.76 63.88 295.03 359.96	318.22 56.57	707.84
(c) Employee benefits expense     190.14     192.62     187.18       (d) Depreciation and amortization expense     33.54     30.34     28.53	382.76 63.88 295.03 359.96	318.22 56.57	707.84
(d) Depreciation and amortization expense 33.54 30.34 28.53	63.88 295.03 359.96	56.57	10.000
	295.03 359.96	-	-
	359.96	453.62	_
(f) Other Expenses 189.75 170.21 239.01		433.02	890.53
	2,013.02	3,471.25	7,008.59
1,1/1,01 1,557,01 1,000,70 1		3,4/1.23	7,008.59
3 Profit / (Loss) from operations before other income,			
finance costs and exceptional items (1-2) 135.07 260.18 238.21	395.24	373.63	992.34
4 Other income 3.40 4.00 44.28	7.39	80.70	156.10
5 Profit / (Loss) from ordinary activities before finance			
costs and exceptional items (3 + 4) 138.47 264.17 282.49	402.63	454.33	1,148.44
6 Finance costs 23.78 19.29 26.73	43.07	33.59	79.44
7 Profit / (Loss) from ordinary activities after finance		Control of the Park Control of the C	
costs but before exceptional items (5 - 6) 114.69 244.88 255.76	359.56	420.74	1,069.00
8 Exceptional items / Prior period items			12.88
9 Profit / (Loss) from ordinary activities before tax (7-			12.00
8) 114.69 244.88 255.76	359.56	420.74	1,081.88
10 Tax expense (Refer Note 3) 42.18 80.97 85.60	123.15	99.20	18.55
11 Net Profit / (Loss) from ordinary activities after tax (9-	143.13	33,20	10.33
10) 72.51 163.91 170.16	236.41	321.54	1,063.33
12 Extraordinary items	230.41	321.34	1,003.33
13 Net Profit / (Loss) for the period (11 + 12) 72.51 163.91 170.16	236.41	321.54	1,063.33
	1,618.64	1,618.64	1,618.64
(Face Value Rs.10/- per share)	1,010.04	1,010.04	1,010.04
15 Reserve excluding Revaluation Reserves as per balance			0 400 01
			9,523.04
sheet of previous accounting year	-		
6.i Earnings per share (before extraordinary items)			
(of Rs.10/- each) (not annualised):			
(a) Basic -in Rs. 0.45 1.01 1.05	1.46	1.99	6.57
(b) Diluted- in Rs. 0.45 1.01 1.05	1.46	1.99	6.57
16.ii Earnings per share (after extraordinary items)			
(of Rs.10/- each) (not annualised):			
(a) Basic -in Rs. 0.45 1.01 1.05	1.46	1.99	6.57
(a) basic - in Rs. 0.45 1.01 1.05 (b) Diluted- in Rs. 0.45 1.01 1.05	1.46	1.99	6.57

## Notes:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14th November, 2016.
- 2 The Statutory Auditors have conducted a Limited Review of the above results for the quarter ended September 30, 2016
- 3 Tax expense includes Current Tax, Mat Credit Entitlement, Deferred Tax and Taxes for earlier years.
- 4 The Company is mainly engaged in the business of "Pharmaceutical Formulations" and there is no other reportable business segment as per Accounting Standard (AS-17).
- 5 Figures of the previous period / year have been reclassified/ regrouped wherever necessary.
- 6 W.e.f 2nd June 2016, excise duty has been levied on the product manufactured at baddi unit at Himachal Pradesh which was exempted earlier by central government being backward state.

Date: 14th November 2016

Place : Mumbai

Rajesh Mahajan

For and on behalf of the Bo

DIN No.: 02000634 Managing Director

## **Brooks Laboratories Limited**

Unaudited Statement of Assets and Liabilities as at September 30, 2016

(Rs. In lacs)

	(Rs. In la		
	Half Year ended		
Particulars	30.09.2016	31.03.2016	
	(Unaudited)	(Audited)	
A   EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share capital	1,618.64	1,618.64	
(b) Reserves and surplus	10,822.78	10,586.35	
	12,441.42	12,204.99	
2 Non-current liabilities			
(a) Long-term borrowings	108.04	34.24	
(b) Deferred tax liabilities (net)	156.63	146.10	
(c) Long-term provisions	84.10	76.18	
	348.77	256.52	
3 Current liabilities			
(a) Short-term borrowings	710.77	528.36	
(b) Trade payables	1,717.15	1,543.63	
(c) Other current liabilities	666.93	589.30	
(d) Short-term provisions	85.68	130.87	
	3,180.53	2,792.16	
TOTAL - EQUITY AND LIABILITIES	15,970.72	15,253.67	
B ASSETS			
1 Non-current assets			
(a) Fixed assets	11,222.86	10,319.40	
(b) Non-current investments	2.00	2.00	
(c) Long-term loans and advances	1,579.29	1,656.05	
	12,804.15	11,977.45	
2 Current assets			
(a) Inventories	559.69	668.90	
(b) Trade receivables	1,831.17	1,891.43	
(c) Cash and bank balances	241.88	222.58	
(d) Short-term loans and advances	509.29	471.55	
(e) Other current assets	24.54	21.76	
	3,166.57	3,276.22	
TOTAL - ASSETS	15,970.72	15,253.67	

For and on behalf of the Board

Date: 14th November 2016

Place: Mumbai

Rajesh Mahajan

DIN No.: 02000634 Managing Director



## The Board of Directors Brooks Laboratories Limited

- 1. We have reviewed the statement of Unaudited Financial Results of Brooks Laboratories Limited (the "Company"), for the quarter / half year ended September 30, 2016 and the Statement of Assets and Liabilities as on that date together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulation, 2015"). This Statement is the responsibility of the Company's management and has been approved by the board of Directors. Our responsibility is to issue a report on the Statement based on our review.
- 2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
- A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S G C O & Co.

Chartered Accountants

Firm Reg. No : 112081W

Suresh Murark Partner

Mem No.: 44739

Place: Mumbai

Date: November 14, 2016

4A, Kaledonia-HDIL, 2<sup>nd</sup> Floor, Sahar Road, Near Andheri Station, Andheri (East), Mumbai - 400 069. India

FRN - 112081V

Tel.: +91 22 6625 6363 Fax: +91 22 6625 6364 E-mail: info@sgco.co.in www.sgco.co.in